- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Glenmark Pharmaceuticals Limited — Updates, 04-03-2026: Press Release
04-03-2026 | 08:36 am
04-03-2026 | 08:36 am
Glenmark Specialty SA received US FDA approval for its Fluticasone Propionate Inhalation Aerosol. This generic, equivalent to FloVent HFA, secures 180 days of market exclusivity. This significantly strengthens Glenmark's respiratory portfolio, targeting an annual market of approximately $520.1 million.
No comments yet. Be the first to comment!